17 results about "Arrhythmic risk" patented technology

This invention discloses an online ECG control method and device for a pacemaker, relating to the field of medical device technology. The method includes: synchronously acquiring raw ECG and transient impedance signals; establishing an artifact waveform model based on impedance attenuation characteristics; removing pacing pulse artifacts; reconstructing a clean ECG signal and marking the capture state; extracting signal waveform features to construct a time-series matrix; inputting it into a pre-trained time-series prediction model to obtain future heart rate trajectories and arrhythmia risk probabilities; constructing a cost function including physiological comfort, safety penalties, and energy efficiency indicators; solving for the optimal pacing parameter vector using the gradient projection method; and driving the pacing circuit to output pulses. This invention effectively solves the artifact interference problem, achieving precise adaptive pacing control based on risk prediction and multi-objective optimization, significantly improving treatment safety and patient comfort.

A non-invasive method for cardiac arrhythmia risk stratification may include identifying, based at least on an electrical recording of a patient, a cardiac depolarization simulation and a cardiac repolarization simulation corresponding to an electrical recording of a patient. One or more regions of increased spatial repolarization gradient in which a first area of a myocardium of the patient exhibits a first repolarization rate that differs from a second repolarization rate of a second area of the myocardium by an amount then divided by the spatial distance between the two regions, by a threshold value may be determined based on the cardiac depolarization simulation and the cardiac repolarization simulation. A risk of cardiac arrhythmia for the patient may be determined based a magnitude of the increased spatial repolarization gradient. Moreover, a treatment plan for the patient may be determined based on the magnitude and / or location of the increased spatial repolarization gradient.

The Cardio-Tox Tissue Engineered Model (TEEM) invention provides a robust in vitro model for cardiotoxicity evaluation using three-dimensional (3D) human heart microtissues to quantify dose-dependent changes in electromechanical activity, resulting in a comprehensive cardiotoxicity and arrhythmia risk assessment of test compounds. The invention also provides a predictive in vitro screening platform for pro-arrhythmic toxicity testing using human three-dimensional cardiac microtissues. The invention enables the screening of environmental and pharmaceutical compounds, chemicals, and toxicants to establish safe human exposure levels.

Systems and methods for assessing a cardiac arrhythmia risk of a patient, such as a risk for developing atrial fibrillation, are disclosed. An exemplary medical-device system includes a risk stratifier circuit configured to, in an absence of prior and present atrial arrhythmia, determine a composite risk of the patient developing a future atrial arrhythmia using a trained machine-learning model and a plurality of features of physiological information sensed from the patient and an arrhythmia monitor circuit configured to adjust an arrhythmia monitoring parameter based at least in part on the composite risk and to detect an atrial arrhythmia event using the adjusted arrhythmia monitoring parameter.

The Cardiac Tissue Engineered Model (TEEM) invention provides a robust in vitro model for cardiotoxicity evaluation using three-dimensional (3D) human heart microtissues to quantify dose-dependent changes in electromechanical activity, resulting in a comprehensive cardiotoxicity and arrhythmia risk assessment of test compounds. The invention also provides a predictive in vitro screening platform for pro-arrhythmic toxicity testing using human three-dimensional cardiac microtissues. The invention enables the screening of environmental and pharmaceutical compounds, chemicals, and toxicants to establish safe human exposure levels.

The Cardio-Tox Tissue Engineered Model (TEEM) invention provides a robust in vitro model for cardiotoxicity evaluation using three-dimensional (3D) human heart microtissues to quantify dose-dependent changes in electromechanical activity, resulting in a comprehensive cardiotoxicity and arrhythmia risk assessment of test compounds. The invention also provides a predictive in vitro screening platform for pro-arrhythmic toxicity testing using human three-dimensional cardiac microtissues. The invention enables the screening of environmental and pharmaceutical compounds, chemicals, and toxicants to establish safe human exposure levels.

The invention provides an arrhythmia risk grading detection method based on a CNN-LSTM palindromic network structure, and the method comprises the following steps: 1, integrating data of a plurality of electrocardiogram public data sets, extracting complete rhythm segments, and forming a rhythm data set which comprises 16 rhythms; 2, dividing the 16 rhythms in the step 1 into three types of rhythm sections according to criticality, and setting the three types of rhythm sections to be normal, need to be focused and criticality-real-time response levels respectively; and step 3, intercepting specific lengths of the three types of rhythm sections, dividing a training set and a test set by adopting a ten-fold cross validation method, and verifying the detection precision. According to the detection method provided by the invention, multi-level and multi-scale more comprehensive spatial-temporal characteristics can be obtained, and a more accurate prediction result can be obtained.

A non-invasive method for cardiac arrhythmia risk stratification may include identifying, based at least on an electrical recording of a patient, a cardiac depolarization simulation and a cardiac repolarization simulation corresponding to an electrical recording of a patient. One or more regions of increased spatial repolarization gradient in which a first area of a myocardium of the patient exhibits a first repolarization rate that differs from a second repolarization rate of a second area of the myocardium by an amount then divided by the spatial distance between the two regions, by a threshold value may be determined based on the cardiac depolarization simulation and the cardiac repolarization simulation. A risk of cardiac arrhythmia for the patient may be determined based a magnitude of the increased spatial repolarization gradient. Moreover, a treatment plan for the patient may be determined based on the magnitude and / or location of the increased spatial repolarization gradient.

Systems and methods for assessing a cardiac arrhythmia risk of a patient, such as a risk for developing atrial fibrillation, are disclosed. An exemplary medical-device system includes a risk stratifier circuit configured to, in an absence of prior and present atrial arrhythmia, determine a composite risk of the patient developing a future atrial arrhythmia using a trained machine-learning model and a plurality of features of physiological information sensed from the patient and an arrhythmia monitor circuit configured to adjust an arrhythmia monitoring parameter based at least in part on the composite risk and to detect an atrial arrhythmia event using the adjusted arrhythmia monitoring parameter.

Embodiments of the disclosure include methods and compositions for improving heart function, including reducing the risk of arrhythmia in an individual in need thereof. In particular embodiments, an individual with a need for improved heart function and / or reduced risk of arrhythmia is provided an effective amount of a shRNA molecule that targets the Sav1 gene.

A method for anesthetizing and / or sedating a subject with shorter QT interval or reduced risk of TdP or lower risk of cardiac arrhythmias, said method comprising administering an effective dose of cipepofol to the subject.

The Cardiac Tissue Engineered Model (TEEM) invention provides a robust in vitro model for cardiotoxicity evaluation using three-dimensional (3D) human heart microtissues to quantify dose-dependent changes in electromechanical activity, resulting in a comprehensive cardiotoxicity and arrhythmia risk assessment of test compounds. The invention also provides a predictive in vitro screening platform for pro-arrhythmic toxicity testing using human three-dimensional cardiac microtissues. The invention enables the screening of environmental and pharmaceutical compounds, chemicals, and toxicants to establish safe human exposure levels.

The invention provides application of circulating protein IFI30 in predicting the long-term arrhythmia risk of an epilepsy patient and a screening method of the circulating protein IFI30, relates to the technical field of biology and medicine, proves the association between the circulating protein IFI30 and the long-term arrhythmia risk of the epilepsy patient, and can evaluate the long-term arrhythmia risk of the epilepsy patient by detecting the level of IFI30. The invention provides a novel thought and method for risk prediction, diagnosis, treatment and prognosis evaluation of the long-term arrhythmia of the epileptic.

A data-processing apparatus for deriving a parameter value indicative of a subject's risk of a future arrhythmia comprises a processing system (6), configured to, for a plurality of frames (500) of a sequence of two-dimensional magnetic field data frames, each representing the rate of change of a magnetic field in the subject's heart at a respective cardiac-cycle instant within a cardiac cycle, define a vector (510) extending between a minimum-rate-of-change position and a maximum-rate-of-change position. The system (6) is further configured to calculate a frame-pair angle change for a plurality of successive pairs of frames, by calculating the absolute value of the difference in angle (512) of the vector defined for each frame of the pair, and calculate the parameter value by taking a combination of at least two of the frame-pair angle changes.

A method of increasing sodium current in a cardiac cell generally includes introducing into the cardiac cell an miR-448 inhibitor in an amount effective to decrease miR-448 suppression of SCN5A mRNA transcription, thereby increasing sodium current in the cardiac cell. A method of increasing translation of SCN5A mRNA in a cell generally includes introducing into the cell an miR-448 inhibitor in an amount effective to decrease miR-448 suppression of SCN5A mRNA transcription. A method of decreasing arrythmia in a cardiac cell generally includes introducing into the cardiac cell an miR-448 inhibitor in an amount effective to decrease miR-448 suppression of SCN5A mRNA transcription. A method of treating arrythmia in a patient having, or at risk of having, arrythmia generally includes administering to the patient an miR-448 inhibitor in an amount effective to decrease the likelihood or extent of arrythmia in the patient. In some embodiments of all methods, the miR-448 inhibitor can be an miR-448 antagomir or an miR-448 sponge.

The invention concerns a computer-implemented method for the estimation of a risk of heart rhythm disorder in a patient's heart, the method comprising: (S03) receiving a mapping of points (IH) representing a tissue of said heart and each being labelled with a value (Ti) and / or a classification (Ci) indicating a local characteristic; (S2) simulating the propagation of electric signals from inducing locations (ILj), to which is applied virtual induction protocol (IPk); (S3) detecting from each simulation outcome (EAMj,k) whether a self-sustained arrhythmia is induced; (S5) a step of clustering, from simulation outcomes (EAMj,k), inducible sites into groups (GI) of similar inducible sites; (S6) a step of computing, for each group (GI) of similar inducible sites (ILj) and from the number (N) of inducible sites of said group, a risk value (RVI) indicating whether a heart rhythm disorder can occur.